19 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 According to a company press release, Costasis shareholders will receive an upfront payment of $75 million, as well as an additional $180 million in various regulatory and commercial milestones. Corstasis shareholders will also be eligible for low double-digit royalties on sales of Enbumsyt and follow-on products. The transaction is expected to close in Q2 2026. “This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long-term Vision 2040. Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. Enbumsyt’s novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise,” said Sheldon Koenig, President and CEO, Esperion, in the release. “We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders - from patients and providers to employees and shareholders.” “Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need. Today’s acquisition validates our team’s vision and approach,” said Ben Esque, CEO, Corstasis Therapeutics, in the release. “We are excited about the future of Enbumyst in Esperion’s hands and its ability to intervene in the patient setting to treat worsening heart failure at home.” NEWS Glenmark Generic inhaler receives FDA nod Glenmark Pharmaceuticals, a global pharmaceutical company focused on innovation and accessibility, announced FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, on March 4th, 2026. According to a company press release, FDA granted the treatment a Competitive Generic Therapy (CGT) designation, meaning the agency considers it to be bioequivalent and therapeutically equivalent to GSK’s FloVent. According to IQVIA sales data cited in the release, FloVent achieved annual sales of approximately $520.1 million for the 12-month period ending in January 2026. Due to its CGT designation, Fluticasone will receive 180 days of CGT exclusivity upon commercialization. The company expects to begin U.S. distribution later this month. “Receiving approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation marks an important milestone in strengthening our respiratory portfolio in the U.S. The CGT designation and first approved applicant status reflect the technical expertise and dedication of our teams in bringing complex inhalation therapies to market,” said Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals, in the release. “We remain committed to improving access to quality and affordable respiratory treatments for patients and healthcare providers.” SUBSCRIBE TO OUR: NEWSLETTER PRINT MAGAZINE DIGITAL MAGAZINE
RkJQdWJsaXNoZXIy MjY2OTA4MA==